WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT

Product: Xpert HIV-1 Viral Load XC WHO reference number: PQDx 0691-070-00

Xpert HIV-1 Viral Load XC with product code GXHIV-VL-XC-CE-10, manufactured by Cepheid AB, CE-marked regulatory version, was accepted for the WHO list of prequalified in vitro diagnostics and was listed on 24 July 2024.

Summary of WHO Prequalification Assessment for Xpert HIV-1 Viral Load XC

	Date	Outcome
Prequalification listing	24 July 2024	listed
Dossier assessment	18 July 2024	MR
Site inspection(s) of quality	24 March 2022	MR
management system		
Product performance	Quarter (Q) 2 to Q 4 2023	MR
evaluation		

MR: Meets Requirements

Intended use

According to the intended use claim from Cepheid AB, "Xpert HIV-1 Viral Load XC (Extended Coverage) is an in vitro reverse transcription polymerase chain reaction (RT-PCR) test for the quantification of human immunodeficiency virus type 1 (HIV-1) RNA in human EDTA plasma using the automated GeneXpert System¹.

It is intended for use as an aid in clinical management of patients infected with HIV-1.

Xpert HIV-1 Viral Load XC is intended for use in conjunction with clinical presentation and other laboratory markers for disease prognosis and for use as an aid in assessing viral response to antiretroviral treatment as measured by changes in plasma HIV-1 RNA levels from HIV-1 infected individuals.

Xpert HIV-1 Viral Load XC is intended to be performed by trained professional users or trained healthcare workers in laboratory or near-patient testing environments.

Xpert HIV-1 Viral Load XC is not intended to be used as a donor screening test for HIV-1 infection."

¹ Please note the Gene Xpert Edge and Near Patient Testing intended use setting claims were not assessed as part of the WHO PQ assessment.

Assay description

According to the claim of the assay description from Cepheid AB, "GeneXpert Instrument Systems automate and integrate sample preparation, nucleic acid extraction and amplification, and detection of the target sequence in simple or complex samples using realtime RT-PCR. The systems consist of an instrument, personal computer, and preloaded software for running tests and viewing the results. The systems require single-use disposable GeneXpert cartridges that contain the RT-PCR reagents and carry out the sample extraction and RT-PCR processes. Because the cartridges are self-contained, cross-contamination between samples is minimized. For a full description of the systems, refer to the appropriate GeneXpert Dx System Operator Manual, GeneXpert Edge System User's Guide, or GeneXpert Infinity System Operator Manual.

The HIV-1 VL XC test includes reagents for the detection of HIV-1 RNA in samples and two internal controls used for quantitation of HIV-1 RNA. The internal controls are also used to monitor the presence of inhibitor(s) in the RT and PCR reactions. Amplification and detection of HIV-1 RNA is achieved by primers and probes targeted to the highly conserved LTR region and the polymerase gene (dual target) of the HIV-1 genome. The Probe Check Control (PCC) verifies reagent rehydration, PCR tube filling in the cartridge, probe integrity, and dye stability.

The HIV-1 VL XC test is standardized against the 4th World Health Organization (WHO) International Standard for HIV-1 (NIBSC code 16/194).

Component	10 tests
	(product code GXHIV-VL-XC-CE-10)
Xpert HIV-1 Viral Load XC	10
Cartridges with Integrated	
Reaction Tubes	
Disposable 1 mL Transfer	1 bag of 10 per kit
Pipettes	
CD	1 per kit

Test kit contents:

Items required but not provided:

- GeneXpert Dx System, GeneXpert Edge System, or GeneXpert Infinity System (catalog number varies by configuration): GeneXpert instrument, computer with proprietary GeneXpert Software Version 4.7b or higher (GeneXpert Dx System), GeneXpert Edge Software Version 1.0 (GeneXpert Edge System) or higher, Xpertise™ 6.4b or higher (GeneXpert Infinity System), barcode scanner, and appropriate GeneXpert System operator manual.
- Printer: If a printer is needed, contact Cepheid Technical Support to arrange for the purchase of a recommended printer.

- Bleach or sodium hypochlorite.
- Ethanol or denatured ethanol.

Storage:

The test kit should be stored at 2–28 °C.

Shelf-life upon manufacture:

18 months.

Warnings/limitations:

Please refer to the current version of the manufacturer's instructions for use attached to this public report.

Prioritization for prequalification

Based on the established criteria, the Xpert HIV-1 Viral Load XC was given priority for the WHO prequalification assessment.

Product dossier assessment

Cepheid AB submitted an abridged product dossier for Xpert HIV-1 Viral Load XC as per the "Instructions for compilation of a product dossier" (PQDx_018). The information (data and documentation) submitted in the product dossier was reviewed by WHO staff and external technical experts (assessors) appointed by WHO. The manufacturer's responses to the discrepancies found during dossier screening and assessment findings were accepted on 18 July 2024.

Based on the product dossier screening and assessment findings, the product dossier for Xpert HIV-1 Viral Load XC meets WHO prequalification requirements.

Manufacturing site inspection

A desk assessment of Cepheid AB located at Röntgenvägen 5 Solna, 17127 Sweden was conducted from 16-24 March 2022. At the time of considering the product application for Prequalification, the Manufacturer of the product had a well-established quality management system and manufacturing practices in place that would support the manufacture of a product of consistent quality. Routine inspections of the Manufacturing site will be conducted with copies of the WHO Public Inspection Report (WHOPIR) published on the WHO Prequalification web page as per Resolution WHA57.14 of the World Health Assembly. Note that a WHOPIR reflects the information on the most current assessment performed at a manufacturing site for in vitro diagnostic products and summarises the assessment findings.

https://extranet.who.int/pqweb/vitro-diagnostics/who-public-inspection-reports

All published WHOPIRs are with the agreement of the manufacturer.

The onsite inspection was accepted on 25 October 2022.

Based on the site inspection and corrective action plan review, the quality management system for Cepheid AB meets WHO prequalification requirements.

Product performance evaluation

The Xpert HIV-1 Viral Load XC test (Cepheid AB) was evaluated on behalf of WHO by the KEMRI HIV Research Laboratory for clinical performance in the second through fourth quarters of 2023 and by the CDC for analytical performance in the second through fourth quarters of 2023, according to protocol PQDx_215, version 7.

Clinical performance evaluation

In this limited laboratory-based evaluation of clinical performance characteristics, a panel of 566 plasma specimens was used, including 476 HIV-positive and 90 HIV-negative specimens. The specimens were characterized using the following reference assay: cobas HIV-1 Quantitative nucleic acid test for use on the cobas[®] 6800/8800 Systems (Roche Diagnostics GmbH). Two specimens with invalid or error results on repeat testing were excluded from the analysis.

Clinical performance characteristics in comparison with an agreed reference standard			
Bias Limits of agreement	-0.1 log ₁₀ copies/mL -0.501 to 0.298 log ₁₀ copies/mL		
Invalid rate % (N=566)	3.9%		
Sensitivity and specificity for the detection of virological failure at 1000 copies/mL			
Sensitivity % (95% Cl) (N=237)	94.5% (95% CI: 90.8% - 97.0%)		
Specificity % (95% Cl) (N=238)	98.3% (95% CI: 95.8% – 99.5%)		
Specificity among HIV-negative individuals			
Specificity % (95% CI) (N=89)	100% (95% CI: 95.9% -100.0%)		

Analytical performance evaluation

Analytical performance characteristics	
Limit of detection (LoD)	The LoD was estimated at 10.1 IU/mL or 4.9 copies/mL using the conversion factor provided by the manufacturer for plasma. The 95% confidence intervals could not be calculated as all but one concentrations tested gave a hit rate of 100%. The LoD claimed by the manufacturer (13.6 copies/mL) was verified.
Within-run precision (repeatability)	At 1000 copies/mL, CV% were < 2.1% At 10 000 copies/mL, CV% were < 1.4%
Within-laboratory precision	At 1000 copies/mL, CV% were < 2.1%
(reproducibility)	At 10 000 copies/mL, CV% were < 1.9%
Linearity	Linearity of the assay was verified for subtypes A, B, C and AG over a range of viral loads from 100 to 1,000,000 copies/mL. For subtype D, results were linear, but with a slope of 0.71. The study is due to be repeated and the public report will be updated accordingly.
Cross-contamination / carry-over	No cross-contamination was observed when high positive and negative specimens were tested alternatively.

Operational characteristics and ease of use

This assay requires laboratory equipment, a centrifuge for separation of whole blood and plasma, and can be performed in laboratories with limited facilities. The instrument requires a stable source of electricity and limited physical space. Since the maximum operating temperature of the GeneXpert system is 30°C, positioning the system in an airconditioned space may be required. Furthermore, training and implementation of good laboratory practice is essential to obtaining accurate results. Minimal technical support from the manufacturer or trained representative is needed.

The assay was found easy to use by the operators performing the evaluation, who had received a minimum of a one-day training by the manufacturer prior to the evaluation. All operators were confirmed by the manufacturer as competent for conducting the Xpert HIV-1 Viral Load XC test prior to conducting testing for the evaluation.

Key operational characteristics	
Specimen type(s) and volume	Plasma, 1 mL
Time to result for one test.	90 minutes
Operator hands-on time for one test	4 minutes
Level of automation	Fully automated
Quality controls	QC are not provided by the manufacturer; however internal controls are present in the test cartridge.
Operating temperature	15-30°C
Result display and connectivity	Results are displayed on the instrument-connected computer. They may be printed using a standard printer. The results can be exported to the laboratory information system and other health information systems.
Power sources	Main power The use of a UPS is recommended, as stable electricity is required.
Biosafety (outside of infectious specimen handling)	Operators reported no biosafety concerns for the user. However, chemical hazards are listed in the IFU for reference. Cartridges contain guanidinium thiocyanate.
Waste	The volume of liquid waste is <3mL per test. The volume of solid waste is approx. 4 g per test. Waste disposal requires specific measures due to the presence of guanidinium thiocyanate in the cartridges in addition to usual laboratory biohazard waste disposal procedures.
Calibration	Calibrators are not provided by the manufacturer and are not required. Frequency of GeneXpert System calibration is annually and is conducted by a trained service representative.
Maintenance	A total of 14 steps required that range between daily, weekly, monthly, quarterly, and annual maintenance and at an interval of every 2,000 tests performed.
Other specific requirements	Installation by manufacturer is necessary and correct assay software version.

* Steps for one specimen: each action required to obtain a result for one specimen (excluding specimen collection, instrument management, maintenance/calibration), e.g. add specimen to the cartridge, close the cartridge, scan/type specimen ID, load the cartridge on the instrument, press start (5 steps) OR scan/type specimen ID, load the specimen collection tube into the instrument, press start (3 step)

** Steps for instrument management: each action required daily or per run to set up and shut down the instrument, e. g. switch on instrument, log in, maintain supplies, maintain reagents, discard liquid waste, discard solid waste, archive results, switch off instrument (8 steps)

Based on these results, the performance evaluation for Xpert HIV-1 Viral Load XC meets the WHO prequalification requirements.

However, the linearity results for HIV-1 subtype D showed a slope of 0.71. As a commitment to prequalification, the manufacturer was requested to provide kits to CDC by 31 July 2024 to repeat the linearity assessment with HIV-1 subtype D for investigation. The kits were provided in July 2024, and this commitment is closed. This public report will be updated once the results of this investigation are available.

Labelling review

Commitments for prequalification:

The manufacturer committed to amend the IFU to include the following:

- 1. The intended use population of the product.
- 2. The instruction to collect a new specimen when a specimen yields an INVALID result twice.

Labelling

- 1. Labels
- 2. Instructions for use

1. Labels

1.1 Hazard Label

WARNING
Harmful if swallowed.
Causes mild skin irritation.
Causes eye irritation.
Wash thoroughly after handling.
If skin irritation occurs: Get medical advice/attention.
IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
If eye irritation persists: Get medical advice/attention.
Call a POISON CENTER or doctor/physician if you feel unwell.

1.2 Top kit label

010733294000740917YYMMDD10XXXXXXXX240GXHIV-VL-XC-CE-10



1.3 Kit box labels

Xpert[®] HIV-1 Viral Load XC

LOT 1234567890

YYYY-MM-DD

cepheid. A better way.

Xpert[®]HIV-1 Viral Load XC Lot 1234567890 ☑ YYYY-MM-DD

LBL P/N 302-3270, Rev B



LOT 1234567890

Cepheid. A better way.

Xpert[®]HIV-1 Viral Load XC Lot 1234567890 YYYY-MM-DD

LBL P/N 302-3270, Rev B

1.4 Cartridge label



1.4 Xpert HIV-1 Viral Load XC CD



2. Instructions for use²

 $^{^2}$ English version of the IFU was the one that was assessed by WHO. It is the responsibility of the manufacturer to ensure correct translation into other languages.



Xpert[®] HIV-1 Viral Load XC

REF GXHIV-VL-XC-CE-10

Instructions For Use **C €** 2797 **IVD**



302-4124, Rev. D December 2022

Trademark, Patents, and Copyright Statements

Cepheid[®], the Cepheid logo, GeneXpert[®], and Xpert[®] are trademarks of Cepheid, registered in the U.S. and other countries. All other trademarks are the property of their respective owners.

THE PURCHASE OF THIS PRODUCT CONVEYS TO THE BUYER THE NON-TRANSFERABLE RIGHT TO USE IT IN ACCORDANCE WITH THESE INSTRUCTIONS FOR USE. NO OTHER RIGHTS ARE CONVEYED EXPRESSLY, BY IMPLICATION OR BY ESTOPPEL. FURTHERMORE, NO RIGHTS FOR RESALE ARE CONFERRED WITH THE PURCHASE OF THIS PRODUCT.

© 2020–2022 Cepheid.

See Section 24, Revision History for a description of changes.

Xpert[®] HIV-1 Viral Load XC

For in Vitro Diagnostic Use Only.

1 Proprietary Name

Xpert[®] HIV-1 Viral Load XC

2 Common or Usual Name

HIV-1 VL XC

3 Intended Use

Xpert[®] HIV-1 Viral Load XC (Extended Coverage) is an in vitro reverse transcription polymerase chain reaction (RT-PCR) test for the quantification of human immunodeficiency virus type 1 (HIV-1) RNA in human EDTA plasma using the automated GeneXpert[®] System.

It is intended for use as an aid in clinical management of patients infected with HIV-1.

Xpert[®] HIV-1 Viral Load XC is intended for use in conjunction with clinical presentation and other laboratory markers for disease prognosis and for use as an aid in assessing viral response to antiretroviral treatment as measured by changes in plasma HIV-1 RNA levels from HIV-1 infected individuals.

Xpert[®] HIV-1 Viral Load XC is intended to be performed by trained professional users or trained healthcare workers in laboratory or near-patient testing environments.

Xpert® HIV-1 Viral Load XC is not intended to be used as a donor screening test for HIV-1 infection.

4 Summary and Explanation

Human Immunodeficiency Virus (HIV) is the etiologic agent of Acquired Immunodeficiency Syndrome (AIDS). HIV can be transmitted through sexual contact, exposure to infected blood, body fluids, or blood products, prenatal infection of a fetus, or perinatal or postnatal infection of a newborn.

Untreated HIV-1 infection is characterized by high-level viral production and CD4 T-cell destruction, despite an often lengthy clinical latency, to significant net loss of CD4 T cells and AIDS.

HIV diagnostics continue to be important for managing the treatment and care of HIV infected patients. Measurement of blood plasma HIV-1 RNA viral load using nucleic acid-based molecular diagnostic assays has been established as standard of care for assessing HIV-positive patient prognosis and response to antiretroviral therapy. Assessment of viral load levels is a strong predictor of the rate of disease progression and, by itself or in combination with CD4 T-cell counts, has great prognostic value.^{1,2}

The HIV-1 VL XC test uses real-time reverse transcription polymerase chain reaction (RT-PCR) technology to achieve high sensitivity for the quantitative detection of HIV-1 RNA in human plasma from HIV-1 infected individuals.

5 Principle of the Procedure

GeneXpert Instrument Systems automate and integrate sample preparation, nucleic acid extraction and amplification, and detection of the target sequence in simple or complex samples using real-time RT-PCR. The systems consist of an instrument, personal computer, and preloaded software for running tests and viewing the results. The systems require

single-use disposable GeneXpert cartridges that contain the RT-PCR reagents and carry out the sample extraction and RT-PCR processes. Because the cartridges are self-contained, cross-contamination between samples is minimized. For a full description of the systems, refer to the appropriate *GeneXpert Dx System Operator Manual*, *GeneXpert Edge System User's Guide*, or *GeneXpert Infinity System Operator Manual*.

The HIV-1 VL XC test includes reagents for the detection of HIV-1 RNA in samples and two internal controls used for quantitation of HIV-1 RNA. The internal controls are also used to monitor the presence of inhibitor(s) in the RT and PCR reactions. Amplification and detection of HIV-1 RNA is achieved by primers and probes targeted to the highly conserved LTR region and the polymerase gene (dual target) of the HIV-1 genome. The Probe Check Control (PCC) verifies reagent rehydration, PCR tube filling in the cartridge, probe integrity, and dye stability.

The HIV-1 VL XC test is standardized against the 4th World Health Organization (WHO) International Standard for HIV-1 (NIBSC code 16/194).³

6 Materials Provided

The HIV-1 VL XC kit contains sufficient reagents to process 10 samples. The kit contains the following:

HIV-1 VL XC Cartridges with Integrated Reaction 10 Tubes

CD	1 per kit
Disposable 1 mL Transfer Pipettes	10 per kit
Proteinase K Reagent	0.48 mL per cartridge
Binding Reagent	2.4 mL per cartridge
Elution Reagent	1.5 mL per cartridge
Rinse Reagent	0.5 mL per cartridge
Lysis Reagent (Guanidinium Thiocyanate)	2.0 mL per cartridge
Bead 1, Bead 2, and Bead 3 (freeze-dried)	1 of each per cartridge

Assay Definition File (ADF)

Instructions to import ADF into GeneXpert software

Instructions for Use (Package Insert)

Note Safety Data Sheets (SDS) are available at www.cepheid.com or www.cepheidinternational.com under the SUPPORT tab.

Note The bovine serum albumin (BSA) in the beads within this product was produced and manufactured exclusively from bovine plasma sourced in the United States. No ruminant protein or other animal protein was fed to the animals; the animals passed ante- and post-mortem testing. During processing, there was no mixing of the material with other animal materials.

7 Storage and Handling

- Store the HIV-1 VL XC test cartridges at 2-28 °C.
- Prior to use, bring the HIV-1 VL XC test cartridges to 15-30 °C if they have been stored cold.
- Do not open the cartridge lid until you are ready to perform the test.
- Use cartridge within 4 hours after opening the cartridge lid and adding sample.
- Do not use a cartridge that has leaked.
- Do not use cartridges that previously have been frozen.
- Do not use a cartridge past the expiration date.

8 Materials Required but not Provided

- GeneXpert Dx System, GeneXpert Edge System, or GeneXpert Infinity System (catalog number varies by configuration): GeneXpert instrument, computer with proprietary GeneXpert Software Version 4.7b or higher (GeneXpert Dx System), GeneXpert Edge Software Version 1.0 (GeneXpert Edge System) or higher, Xpertise[™] 6.4b or higher (GeneXpert Infinity System), barcode scanner, and appropriate GeneXpert System operator manual
- Printer: If a printer is needed, contact Cepheid Technical Support to arrange for the purchase of a recommended printer.
- Bleach or sodium hypochlorite
- Ethanol or denatured ethanol

9 Warnings and Precautions

- For *in vitro* diagnostic use only.
- Treat all biological samples, including used cartridges, as if capable of transmitting infectious agents. Because it is often impossible to know which might be infectious, all biological samples should be treated with standard precautions. Guidelines for samples handling are available from the U.S. Centers for Disease Control and Prevention and the Clinical and Laboratory Standards Institute (CLSI).^{4,5}
- Follow your institution's safety procedures for working with chemicals and handling biological samples.
- Appropriate safety measures should be taken in the event of a splash that may occur using bleach and facilities for adequate eye washing or skin rinsing are advised to care for such events.
- Biological samples, transfer devices, and used cartridges should be considered capable of transmitting infectious agents requiring standard precautions. Follow your institution's environmental waste procedures for proper disposal of used cartridges and unused reagents. These materials may exhibit characteristics of chemical hazardous waste requiring specific disposal. If country or regional regulations do not provide clear direction on proper disposal, biological samples and used cartridges should be disposed per WHO [World Health Organization] medical waste handling and disposal guidelines.⁶
- Do not substitute HIV-1 VL XC test reagents with other reagents.
- Do not use a cartridge that has been dropped after removing it from the packaging.
- Do not shake the cartridge. Shaking or dropping the cartridge after opening the lid may yield invalid results.
- Do not place the sample ID label on the cartridge lid or on the barcode label.
- Each single-use HIV-1 VL XC test cartridge is used to process one sample. Do not reuse spent cartridges.
- Do not use a cartridge that has a damaged reaction tube.
- Each single-use disposable pipette is used to transfer one sample. Do not reuse spent disposable pipettes.
- If using a precision pipette: Each single use disposable pipette tip is used to transfer one sample. Do not reuse spent pipette tips.
- Wear clean lab coats and gloves. Change gloves between processing each sample.
- In the event of contamination of the work area or equipment with samples, thoroughly clean the contaminated area with a freshly prepared solution of 0.5% sodium hypochlorite (or a 1:10 dilution of household chlorine bleach). Follow by wiping the surface with 70% ethanol. Let the work surfaces dry completely before proceeding.
- For Instrument System cleaning and disinfecting instructions, refer to the appropriate GeneXpert Dx System Operator Manual, GeneXpert Edge System User's Guide, or GeneXpert Infinity System Operator Manual.

10 Chemical Hazards^{7,8}

Signal Word: WARNING

UN GHS Hazard Statements

- Harmful if swallowed.
- Causes mild skin irritation.
- Causes eye irritation.

UN GHS Precautionary Statements Prevention

• Wash thoroughly after handling.

Response

- Call a POISON CENTER or doctor/physician if you feel unwell.
- If skin irritation occurs: Get medical advice/attention.
- IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
- If eye irritation persists: Get medical advice/attention.

11 Sample Collection, Transport, and Storage

Whole blood should be collected in BD Vacutainer[®] PPT[™] Plasma Preparation Tubes for Molecular Diagnostic Test Methods, or in sterile collection tubes using K2 EDTA as the anticoagulant. Whole blood should be centrifuged to separate the plasma and red blood cells per the manufacturer's instructions.

- A minimum of 1 mL plasma is required for the HIV-1 VL XC test. If using the transfer pipette included in the kit, fill the transfer pipette with plasma to just below the bulb to transfer the required volume. Alternatively, if using a precision pipette, a minimum of 1 mL plasma is required. See Section 12.2 Preparing the Cartridge, step 6.
- Prior to plasma separation, whole blood collected in BD Vacutainer PPT Plasma Preparation Tubes for Molecular Diagnostic Test Methods, or in sterile collection tubes using K2 EDTA as the anticoagulant may be held at 2–30 °C for up to 24 hours.
- Plasma should be removed from the primary collection tube after centrifugation for storage. Plasma separated from whole blood may be held in secondary tubes at 2–35 °C for up to 24 hours, at 2–8 °C for up to 7 days or frozen (≤ -18 °C and ≤ -70 °C) for up to 6 weeks prior to testing.
- Plasma samples are stable for up to five freeze/thaw cycles. Thaw sample at 15-30 °C.
- Transportation of whole blood or plasma samples must comply with country, federal, state and local regulations for the transportation of etiologic agents.

12 Procedure

12.1 Preparing the Sample

- 1. Following centrifugation of whole blood samples, plasma may be pipetted directly into the test cartridge. Sufficient volume is critical to obtaining valid test results (see Section 12.2 Preparing the Cartridge).
- 2. Completely thaw and equilibrate frozen plasma samples to 15-30 °C prior to testing.
- 3. Remove plasma samples stored at 2-8 °C from the refrigerator and equilibrate to 15-30°C prior to testing.
- 4. Vortex plasma samples stored at 2–8 °C or frozen and thawed for 15 seconds before use.
- 5. If the plasma samples are cloudy, clarify by a quick (10 second) centrifugation before use.

12.2 Preparing the Cartridge

Note When using the GeneXpert Dx System or GeneXpert Edge System, start the test within 4 hours of adding the sample to the cartridge. If using a GeneXpert Infinity System, be sure to start the test and put the cartridge on the conveyor within 30 minutes of adding the Sample Reagent-treated sample to the cartridge. Remaining shelf-life is tracked by the Xpertise Software so that tests are run prior to the 4-hour onboard expiration.

Note Pipetting no plasma or less than 1 mL of plasma into the cartridge will trigger an insufficient volume error (ERROR 2096 and ERROR 2097 respectively) preventing the instrument from running the sample.

- 1. Wear protective disposable gloves.
- 2. Allow HIV-1 VL XC test cartridges and sample to equilibrate to 15–30 °C prior to pipetting plasma into the cartridge.
 - Do not pipette plasma into a cartridge that is cold (below 15°C).
- 3. Inspect the test cartridge for damage. If damaged, do not use it.
- 4. Label the cartridge with sample identification.
- 5. Open the lid of the test cartridge.
- 6. Add the sample to the test cartridge.

- If using the *transfer pipette* included in the kit (Figure 1), fill the pipette to just below the bulb to transfer at least 1 mL plasma from the tube (Figure 1). Make sure no large air bubbles are created in the pipette tip while filling the pipette. Empty the contents of the pipette into the sample chamber of the cartridge (Figure 2).
- If using a *precision pipette*, pre-wet the pipette tip once, by filling the pipette tip with plasma and emptying it into the tube. Then, using the pre-wet pipette tip, fill the pipette with at least 1 mL plasma from the tube. Empty the contents of the pipette into the sample chamber of the cartridge (Figure 2).

Note Do not remove the thin plastic film that covers the inner ring of the cartridge.



Figure 1. Transfer Pipette

Number	Description
1	Empty pipette
2	Filled pipette
3	Bulb
4	Fill plasma to just below the bulb.



Figure 2. Cartridge (Top View)

7. Close the cartridge lid. Ensure the lid snaps firmly into place.

13 Running the Test

- For the GeneXpert Dx System, see Section 13.1.
- For the GeneXpert Edge System, see Section 13.2.
- For the GeneXpert Infinity System, see Section 13.3.

13.1 GeneXpert Dx System

13.1.1 Starting the Test

Before you start the test, make sure that:

- Important The system is running the correct GeneXpert Dx software version shown in section Materials Required but Not Provided.
 - The correct assay definition file is imported into the software.

This section lists the basic steps for running the test. For detailed instructions, see the *GeneXpert Dx System Operator Manual*.

Note The steps you follow can be different if the system administrator changed the default workflow of the system.

- 1. Turn on the GeneXpert Dx System, then turn on the computer and log on. The GeneXpert software will launch automatically. If it does not, double-click the GeneXpert Dx software shortcut icon on the Windows[®] desktop.
- 2. Log on using your username and password.
- In the GeneXpert System window, click Create Test. The Create Test window displays. The Scan Patient ID barcode dialog box displays.
- 4. Scan or type in the Patient ID. If typing the Patient ID, make sure the Patient ID is typed correctly. The Patient ID is associated with the test results and displays in the View Results window and all the reports. The Scan Sample ID barcode dialog box displays.
- 5. Scan or type in the Sample ID. If typing the Sample ID, make sure the Sample ID is typed correctly. The Sample ID is associated with the test results and displays in the View Results window and all the reports. The Scan Cartridge Barcode dialog box displays.
- 6. Scan the barcode on the cartridge. Using the barcode information, the software automatically fills the boxes for the following fields: Select Assay, Reagent Lot ID, Cartridge SN, and Expiration Date.

If the barcode on the cartridge does not scan, then repeat the test with a new cartridge. If you have scanned the cartridge barcode in the software and the assay definition file is not available, a screen displays indicating the assay definition file is not loaded on the system. If this screen displays, contact Cepheid Technical Support.

- 7. Click Start Test. In the dialog box that displays, type your password, if required.
- 8. Open the instrument module door with the blinking green light and load the cartridge.
- **9.** Close the door. The test starts and the green light stops blinking. When the test is finished, the light turns off.
- 10. Wait until the system releases the door lock before opening the module door, then remove the cartridge.
- 11. Dispose of the used cartridges in the appropriate specimen waste containers according to your institution's standard practices.

13.1.2 Viewing and Printing Results

This section lists the basic steps for viewing and printing results. For more detailed instructions on how to view and print the results, see the *GeneXpert Dx System Operator Manual*.

- 1. Click the **View Results** icon to view results.
- 2. Upon completion of the test, click the **Report** button of the **View Results** window to view and/or generate a PDF report file.

13.2 GeneXpert Edge System

(May not be available in all countries)

13.2.1 Starting the Test

Important Before you start the test, make sure that the correct assay definition file (ADF) is imported into the software.

This section lists the basic steps for running the test. For detailed instructions, see the GeneXpert Edge System User's Guide.

- Note The steps you follow can be different if the system administrator changed the default workflow of the system.
 - 1. Put on a clean pair of gloves.
 - 2. Turn on the GeneXpert Edge instrument. The power switch is on the back of the instrument.
 - 3. Turn on the tablet computer and log on.
 - Windows 7: The Windows 7 account screen displays. Touch the Cepheid-Admin icon to continue.
 - Windows 10: The Windows Lock screen displays. Swipe up to continue.

The **Windows Password** screen displays.

- 4. Touch **Password** to display the keyboard, then type your password.
- Touch the **arrow** button at the right of the password entry area. The GeneXpert Edge software loads automatically, and the **Welcome** screen displays shortly thereafter.
- Touch the TOUCH HERE TO BEGIN button. The VIEW PREVIOUS TESTS button initially displays. The NEW TEST button displays on the Home screen within 3 minutes when the instrument is ready to run.
- 7. Touch the RUN NEW TEST button on the Home screen.
- 8. Follow the on-screen instructions:
 - a) Scan patient/sample ID using the barcode scanner, or manually enter the patient/sample ID.
 - b) Confirm the patient/sample ID.
 - c) Scan the cartridge barcode.

The Select Assay field automatically fills. Touch YES if the displayed information is correct.

Note If the barcode on the cartridge does not scan or scanning the barcode results in an error message, then repeat the test with a new cartridge. If you have scanned the cartridge barcode in the software and the assay definition file is not available, a screen displays indicating the assay definition file is not loaded on the system. If this screen displays, contact Cepheid Technical Support.

- d) Confirm test Once the ADF has been selected, confirm the assay.
- e) **Cartridge preparation** The cartridge preparation is also described in the Preparing the Specimen section. Follow the video or instructions on how to prepare the specimen.
- f) Load cartridge Open the module door with the blinking green light. Load the cartridge with the barcode facing the operator. Close the door.

The green light stops blinking, and the test starts. Test in Progress displays on the screen.

g) Remove cartridge

When the test is done (green light goes out), the door automatically unlocks. Follow the displayed instructions on how to remove the cartridge. Dispose of the used cartridge and gloves in an appropriate specimen waste container according to your institution's standard practices.

9. Touch CONTINUE to view the result of the test that has just completed. Touch CONTINUE again to go back to Home screen.

This completes the procedure for running a test.

13.2.2 Viewing and Printing Results

This section lists the basic steps for viewing and printing results. For more detailed instructions on how to view and print the results, see the *GeneXpert Edge System User's Guide*.

Note If reporting results using a LIS, confirm that LIS results match system results for the patient ID field; if results conflict, report the system results only.

- 1. Touch the VIEW PREVIOUS TESTS button on the Home screen.
- 2. On the Select Test screen, select the test by either touching the test name or using the arrows to select the test.

13.3 GeneXpert Infinity System

13.3.1 Starting the Test

Before you start the test, make sure that:

Important • The system is running the correct Xpertise software version shown in section - Materials Required but Not Provided.

• The correct assay definition file is imported into the software.

This section lists the basic steps for running the test. For detailed instructions, see the GeneXpert Infinity System Operator Manual.

Note The steps you follow can be different if the system administrator changed the default workflow of the system.

- 1. Power up the instrument. The Xpertise software will launch automatically. If it does not, double-click the Xpertise software shortcut icon on the Windows[®] desktop.
- 2. Log on to the computer, then log on to the GeneXpert Xpertise software using your user name and password.
- 3. In the Xpertise Software Home workspace, click Orders and in the Orders workspace, click Order Test. The Order Test - Patient ID workspace displays.
- 4. Scan or type in the Patient ID. If typing the Patient ID, make sure the Patient ID is typed correctly. The Patient ID is associated with the test results and displays in the **View Results** window and all the reports.
- 5. Enter any additional information required by your institution, and click the **CONTINUE** button. The **Order Test Sample ID** workspace displays.
- 6. Scan or type in the Sample ID. If typing the Sample ID, make sure the Sample ID is typed correctly. The Sample ID is associated with the test results and displays in the **View Results** window and all the reports.
- Click the CONTINUE button. The Order Test - Assay workspace displays.
- 8. Scan the barcode on the cartridge. Using the barcode information, the software automatically fills the boxes for the following fields: Select Assay, Reagent Lot ID, Cartridge SN, and Expiration Date.

If the barcode on the cartridge does not scan, then repeat the test with a new cartridge. If you have scanned the cartridge barcode in the software and the assay definition file is not available, a screen displays indicating the assay definition file is not loaded on the system. If this screen displays, contact Cepheid Technical Support.

After the cartridge is scanned, the Order Test - Test Information workspace displays.

- 9. Verify that the information is correct, and click **Submit**. In the dialog box that displays, type your password, if required.
- Place the cartridge on the conveyor belt. The cartridge automatically loads, the test runs, and the used cartridge are placed into the waste container.

13.3.2 Viewing and Printing Results

This section lists the basic steps for viewing and printing results. For more detailed instructions on how to view and print the results, see the *GeneXpert Infinity System Operator Manual*.

- 1. In the Xpertise Software Home workspace, click the RESULTS icon. The Results menu displays.
- 2. In the Results menu, select the VIEW RESULTS button. The View Results workspace displays showing the test results.
- 3. Click the **REPORT** button to view and/or generate a PDF report file.

14 Quality Control

Each test includes a Sample Volume Adequacy (SVA) control, Internal Quantitative Standard High and Low (IQS-H and IQS-L), Lot Specific Parameters (LSP), and a Probe Check Control (PCC).

- Sample Volume Adequacy (SVA): Ensures that the sample was correctly added to the cartridge. The SVA verifies that the correct volume of sample has been added in the sample chamber. The SVA passes if it meets the acceptance criteria. If the SVA does not pass, an ERROR 2096 will display if there is no sample or an ERROR 2097 if there is not enough sample. The system will prevent the test to be processed.
- Internal Quantitative Standard High and Low (IQS-H and IQS-L): IQS-H and IQS-L are two Armored RNA[®] controls unrelated to HIV that are included in each cartridge and go through the whole test process. They are used for quantitation by using lot specific parameters for the calculation of HIV-1 RNA concentration in the sample. Additionally, IQS-H and IQS-L detect specimen-associated inhibition of the RT-PCR reaction, thereby acting as sample processing controls. The IQS-H and IQS-L pass if Cycle thresholds (Cts) are within valid range.
- Lot Specific Parameters (LSP) for Quantitation Each kit lot has built-in LSP generated from an HIV-1 calibration panel, traceable to the 4th WHO International Standard for HIV-1 (NIBSC code 16/194), and the IQS-H and IQS-L. The LSP are unique for each kit lot and are used to ensure correct quantitation.
- **Probe Check Control (PCC)**: Before the start of the PCR reaction, the GeneXpert Instrument System measures the fluorescence signal from the probes to monitor bead rehydration, reaction tube filling, probe integrity, and dye stability. The PCC passes if the fluorescence signals meet the assigned acceptance criteria.

15 Interpretation of Results

The results are interpreted automatically by the GeneXpert Instrument System from measured fluorescent signals and embedded calculation algorithms and are clearly shown in the **View Results** window (Figure 3 to Figure 11). Possible results are shown in Table 1.

Result	Interpretation			
HIV-1 DETECTED	HIV-1 RNA is detected at XX copies/mL (log X.XX)			
XX copies/mL (log X.XX)	 HIV-1 RNA has quantitative value within the quantitative range of the test - (40-1x10⁷ copies/mL). 			
See Figure 3 and Figure 9.	 IQS-H and IQS-L: PASS. Probe Check: PASS; all probe check results pass. 			
HIV-1 DETECTED	HIV-1 RNA is detected above the analytical measurement range.			
> 1 × 10 ⁷ copies/mL	IQS-H and IQS-L: PASS.			
See Figure 4.	Probe Check: PASS. All probe check results pass.			
HIV-1 DETECTED	HIV-1 RNA is detected below the analytical measurement range.			
< 40 copies/mL	• IQS-H and IQS-L: PASS.			
See Figure 5.	Probe Check: PASS. All probe check results pass.			
HIV-1 NOT DETECTED	HIV-1 RNA is not detected. This result does not infer that the patient has been cleared of the virus.			
See Figure 6 and Figure	IQS-H and IQS-L: PASS.			
10.	Probe Check: PASS. All probe check results pass.			
INVALID	Presence or absence of HIV-1 RNA cannot be determined. Repeat test			
See Figure 7.				
	 IQS-H and/or IQS-L: FAIL; Cycle thresholds (Cts) are not within valid range. Probe Check: PASS. All probe check results pass. 			
ERROR	Presence or absence of HIV-1 RNA cannot be determined. Repeat test according to the instructions in Section 16.2.			
See Figure 8.	 Probe Check: FAIL; all or one of the probe check results fail. 			

Table 1. Results and Interpretation

Result	Interpretation
NO RESULT See Figure 11.	Presence or absence of HIV-1 RNA cannot be determined. Repeat test according to the instructions in Section 16.2. A NO RESULT indicates that insufficient data were collected. For example, the operator stopped a test that was in progress.

Results can be converted from copies/mL to IU/mL within the software. Please see the *GeneXpert Dx System Operator Manual* or **Note** the *GeneXpert Infinity System Operator Manual* for instructions on how to change this setting.

The conversion factor for the HIV-1 VL XC test is 1 copy = 2.06 International Unit (IU).

Note Assay screenshots are for example only. The version number may vary from the screenshots shown in this package insert.



Figure 3. Result: HIV-1 Detected and Quantified (GeneXpert Dx System and GeneXpert Infinity System)



Figure 4. Result: HIV-1 Detected but with titer above the quantitative range of the test (GeneXpert Dx System and GeneXpert Infinity System)



Figure 5. Result: HIV-1 Detected but with titer below the quantitative range of the test (GeneXpert Dx System and GeneXpert Infinity System)







Figure 7. Invalid Result (GeneXpert Dx System and GeneXpert Infinity System)

Test Result	Analyte Result	Detail	Errors	History	Support
Assay Name	Xpert HIV-1 Viral Lo	ad XC	Version	1 1	
Test Result	ERROR				
For In Vitro Dia	agnostic Use Only.				
					<no availables<="" data="" th=""></no>

Figure 8. Result: Error (GeneXpert Dx System and GeneXpert Infinity System)

A123456	284986981
Assay Xpert HIV-1 Viral Load XC	
Result	Start Time
HIV-1 DETECTED 4.93E05	12/01/21 18:27:48 Test Disclaimer
copies/mL (log 5.69)	For In Vitro Diagnostic Use Only.

Figure 9. Result: HIV-1 Detected (GeneXpert Edge System)

GeneXpert [®] Test Result	VIEW PREVIOUS TESTS HOME (A)
Patient/Sample ID B123456 Assay Xpert HIV-1 Viral Load XC Result HIV-1 NOT DETECTED	Cartridge S/N 239021308 Start Time 12/01/21 18:27:48 Test Disclaimer For In Vitro Diagnostic Use Only.
	Cepheid.

Figure 10. Result: HIV-1 Not Detected (GeneXpert Edge System)

Figure 11. No Result-Repeat Test (GeneXpert Edge System)

16 Retests

16.1 Reasons to Repeat the Test

If any of the test results mentioned below occur, repeat the test according to instructions in Section 16.2.

• An **INVALID** result indicates one or more of the following:

- The IQS-H and/or IQS-L Cts are not within valid range.
- The sample was not properly processed, or PCR was inhibited.
- An **ERROR** indicates that the test was aborted. Possible causes include: insufficient volume of sample was added, the reaction tube was filled improperly, a reagent probe integrity problem was detected, or the maximum pressure limit was exceeded.
- A **NO RESULT** indicates that insufficient data were collected. For example, the operator stopped a test that was in progress, or a power failure occurred.

16.2 Retest Procedure

If the result of a test is **INVALID**, **ERROR**, or **NO RESULT**, use a new cartridge to retest the affected sample (do not re-use the cartridge).

- 1. Remove a new cartridge from the kit.
- 2. Go to Section 12, Procedure, including Section 12.2, Preparing the Cartridge, and Section 12.3, Starting the Test.

17 Limitations

- Good laboratory practice and changing gloves between handling samples are recommended to avoid contamination of samples or reagents.
- Rare mutations, deletions or insertions within the target regions of the HIV-1 VL XC test may affect primer and/or probe binding resulting in under-quantitation or failure to detect the virus.
- Patients who have received CAR-T therapies may display positive results with Xpert (HIV-1 Qual XC, HIV-1 VL, etc.) as the result of the presence of the LTR target within certain chimeric antigen receptor T-cell (CAR-T) products. Additional confirmatory testing should be performed to determine the patient's HIV status in people who have received CAR-T treatment.
- The HIV-1 VL XC test has been validated only for use with K2 EDTA and PPT-EDTA plasma. Testing of other sample types may lead to inaccurate results.
- A negative test result does not preclude HIV-1 infection. Results from the HIV-1 VL XC test should be interpreted in conjunction with clinical presentation and other laboratory markers.
- Prior to switching from one technology to the next, Cepheid recommends that users perform method correlation studies in their laboratory to qualify technology differences.
- Reliable results are dependent on adequate sample collection, transport, storage and processing.
- Quantitation of HIV-1 RNA is dependent on the number of virus particles present in a sample and may be affected by sample collection methods, patient factors (i.e., age, presence of symptoms), and/or stage of infection.
- A sample that yields an INVALID result twice may contain an inhibitor; retesting is not recommended.

18 Performance Characteristics

18.1 Analytical Sensitivity (Limit of Detection (LoD) and Inclusivity)

The limit of detection (LoD) of the HIV-1 VL XC test was determined for group M subtype B by testing serial dilutions prepared from the WHO 4th International Standard for HIV-1 (NIBSC code: 16/194) in HIV-1 negative K2 EDTA plasma. In total six different concentration levels of the WHO International Standard and one negative were tested with three kit lots. Each concentration level was tested across three days with 24 replicates per kit lot for a total of 72 replicates per concentration level.

The results are shown in Table 2. The study demonstrated that the HIV-1 VL XC test detected HIV-1 RNA for the WHO International Standard at a concentration of 13.6 copies/mL in K2 EDTA plasma with a positivity rate of 95% as determined by PROBIT regression.

Group/Subtype	Nominal HIV-1 Concentration (copies/mL)	Number of Valid Replicates	Number of Positive Replicates	Positivity Rate (%)	LoD with 95% Probability Estimated by Probit (95% Confidence Interval)
Group M/	0	72	0	0	13.6 copies/
Subtype B	1	72	13	18	mL (11.7-15.6)
	2.5	72	31	43	
	5	72	45	63	
	10	72	60	83	
	20	72	70	97	
	40	72	72	100	

Table 2. Limit of Detection for the HIV-1 VL XC testusing the 4th WHO International Standard for HIV-1

The limit of detection for the HIV-1 group M subtypes A, C, D, F, G, H, J, K, CRF-A/B, CRF-A/E, CRF-A/G, CRF-B/C, CRF-06, group N, group O and group P was determined by testing serial dilutions of cell culture stocks or clinical specimens representing each HIV-1 group and subtype in HIV-1 negative K2 EDTA plasma. In total six concentration levels of each HIV-1 group and subtype was tested with one kit lot across three days for a total of 24 replicates per concentration level.

The assignment of the nominal concentration of the cell culture stocks and clinical specimens was determined using CEmarked HIV-1 viral load tests.

The HIV-1 RNA concentration that can be detected with a positivity rate of 95% was determined by PROBIT regression. The results for each HIV-1 group M subtypes A, C, D, F, G, H, J, K, CRF-A/B, CRF-A/E, CRF-A/G, CRF-B/C, CRF-06, group N, group O and group P are shown in Table 3.

Group	Subtype	LoD by PROBIT (copies/mL)	95% Confidence Interval (copies/mL)
Group M	A	15.9	12.1-19.7
	С	13.2	10.2-16.3
	D	17.7	13.5-21.8
	F	18.1	14.5-21.6
	G	18.0	13.7-22.3
	Н	7.9	6.2-9.5
	J	14.2	10.6-17.7
	К	16.9	12.7-21.0
	CRF A/B	13.1	9.9-16.3
	CRF A/E	14.2	10.7-17.6
	CRF A/G	17.4	13.2-21.6
	CRF B/C	17.0	13.3-20.8
	CRF 06	10.8	8.4-13.2
Group N	N/A	16.5	12.2-20.8

Table 3. Limit of Detection for HIV-1 group M subtypes A, C, D, F, G, H, J, K, CRF-A/B, CRF-A/E, CRF-A/G, CRF-B/C, CRF-06, group N, group O and group P in K2 EDTA Plasma

Group	Subtype	LoD by PROBIT (copies/mL)	95% Confidence Interval (copies/mL)
Group O	N/A	9.0	6.8-11.1
Group P	N/A	4.9	3.9-5.9

18.2 Limit of Quantitation (LoQ)

The lower limit of quantitation (LLoQ) is defined as the lowest concentration of HIV-1 RNA that is quantified with acceptable precision and trueness and is determined using the total analytical error (TAE) and an approach based upon the difference between two measurements. The TAE for HIV-1 VL XC was calculated using estimates determined through analysis of data from the LoD study (WHO International Standard) and data from testing performed on three HIV-1 subtype B clinical specimens in K2 EDTA plasma (value assigned with a CE-marked HIV-1 Viral Load test) at a concentration of 40 HIV-1 RNA copies/mL using two kit lots with 16 replicates per kit lot.

TAE was estimated with the Westgard model according to CLSI guideline with the criterion, [(Absolute Bias) + 2 SDs) $\leq 1 \log_{10} \text{ copies/mL}$].⁹ The difference between two measurements approach was evaluated with the criterion, [(2 x SQRT(2) x SD) $\leq 1 \log_{10} \text{ copies/mL}$].

The LLoQ analyses for each specimen are presented in Table 4. The result demonstrates that the HIV-1 VL XC test can determine 40 copies/mL HIV-1 RNA with an acceptable trueness and precision.

HIV-1 Subtype B Sample	Kit Lot	N	Nominal HIV-1 Conc. (log ₁₀ copies/ mL)	Observed HIV-1 Conc. (log ₁₀ copies/ mL)	Bias	Total SD	Total Analytical Error ^a	Two Measurement Approach ^b
WHO	1	24	1.60	1.51	-0.09	0.14	0.37	0.39
	2	24	1.60	1.48	-0.12	0.17	0.47	0.49
	3	24	1.60	1.56	-0.04	0.31	0.65	0.87
Clinical	1	16	1.60	1.65	0.05	0.10	0.25	0.29
Specimen 1	2	16	1.60	1.63	0.03	0.11	0.25	0.32
Clinical	1	16	1.60	1.80	0.20	0.12	0.44	0.35
2	2	16	1.60	1.73	0.13	0.12	0.37	0.34
Clinical	1	16	1.60	1.45	-0.15	0.29	0.72	0.81
Specimen 3	2	16	1.60	1.62	0.02	0.16	0.33	0.45

Table 4. Determination of the LLoQ for the HIV-1 VL XC Test

^a TAE calculated according to the Westgard model where [TAE = $|Bias| + (2 \times SD) \le 1 \log_{10} copies/mL$] ensuring there is a 95% probability that the measurement will be less than 1 log₁₀ copies/mL from the true value.

^b Two measurements approach [2 × (SQRT(2) × SD) \leq 1 log₁₀ copies/mL] indicates that a difference of less than 1 log₁₀ copies/mL can be explained by a random measurement error.

18.3 Precision and Reproducibility

The precision and reproducibility of the HIV-1 VL XC test was established in a three-site, blinded study using a sevenmember panel of HIV-1 reference material spiked into HIV-1 negative EDTA plasma with RNA concentrations that span the HIV-1 VL XC test quantitation range. Two operators at each of the three study sites tested one panel of seven samples twice per day over six testing days. Two sites used GeneXpert Dx instruments and one site used an Infinity-80 instrument. Three kit lots of the HIV-1 VL XC test were used in the study. The precision/reproducibility study was evaluated in accordance with CLSI guideline.¹⁰

The reproducibility of the HIV-1 VL XC test was evaluated by using nested ANOVA with terms for Site/Instrument, Lot, Operator, Day, Run, and Within-Run. The standard deviation and the percentage of variability due to each component of the log₁₀ HIV-1 transformed concentrations were calculated (see Table 5).

Expected	Variance Source															
HIV-1 RNA	N	N		ite	Lot Op		Ope	perator Day		ay	ay Run		Within-Run		Total	
Concentration (copies/mL)		Wear	SDb	(%)	SD	(%)	SD	(%)	SD	(%)	SD	(%)	SD	(%)	SD	CV (%) ^c
40 cp/mL	143 ^d	1.59	0.01	0.55	0.03	2.15	0.04	5.97	0.05	7.80	0.00	0.00	0.16	83.53	0.17	10.69
200 cp/mL	144	2.28	0.02	5.52	0.03	9.27	0.01	2.08	0.00	0.00	0.00	0.00	0.09	83.14	0.10	4.39
1x10 ³ cp/mL	144	2.99	0.00	0.00	0.02	9.75	0.00	0.00	0.02	13.86	0.00	0.00	0.06	76.38	0.06	2.01
1x10 ⁴ cp/mL	144	3.98	0.01	4.72	0.02	15.66	0.00	0.00	0.00	1.00	0.01	6.19	0.04	72.43	0.05	1.26
1x10 ⁶ cp/mL	143 ^e	6.01	0.01	3.40	0.03	15.35	0.00	0.00	0.00	0.00	0.00	0.00	0.06	81.25	0.07	1.16
1x10 ⁷ cp/mL	144	6.96	0.00	0.00	0.04	17.70	0.00	0.00	0.03	10.97	0.00	0.00	0.09	71.32	0.10	1.44

|--|

^a Mean HIV-1 RNA cp/mL log₁₀

^b SD in \log_{10} ^c CV = (total SD/mean)*100

^d 1 sample with "HIV-1 Not Detected" result was excluded

^e 1 sample with "Error" result was excluded

18.4 Linear Range

The linear range of the HIV-1 VL XC test was determined by analysis of a nine-member panel ranging from 15 copies/mL to 1.2 x 107 copies/mL prepared by parallel dilutions of HIV-1 reference material (HIV-1 subtype B) in HIV-1 negative K2 EDTA plasma. The reference material used was calibrated to the WHO 4th International standard for HIV-1 (NIBSC code: 16/194). The panel was tested using two kit lots of the HIV-1 VL XC test, resulting in total 24 or 48 replicates per panel member.

The linearity analysis was performed according to CLSI guideline.¹¹ The results are presented in Figure 12. The HIV-1 VL XC test is linear from 20 copies/mL to 1x107 copies/mL with an R²>99.



Figure 12. Linearity for the HIV-1 VL XC Test

18.5 Analytical Reactivity (Inclusivity)

The analytical reactivity (inclusivity) for the HIV-1 VL XC test was demonstrated by testing HIV-1 Group M, subtypes A, B, C, D, F, G, H, J, K, CRF-A/B, CRF-A/E, CRF-A/G, CRF-B/C, CRF-06, group N, group O and group P at multiple concentration levels spanning the test's quantitative range of 40-1x10⁷ copies/mL depending on subtype/group. Each concentration level was tested in replicates of minimum eight using two kit lots of the HIV-1 VL XC test. The mean \log_{10} concentration obtained for each subtype/group and concentration level was quantified within \pm 0.5 \log_{10} of the assigned input concentration and each linear regression had an R2 >0.98 (see Table 6, Table 7, and Table 8).

HIV-1 Group M subtype	Nominal Concentration (log ₁₀ copies/mL)	HIV-1 VL XC Result (log ₁₀ copies/mL)	Delta (log ₁₀ copies/mL)	R ²
A	6.0	5.91	0.09	0.996
	4.0	3.99	0.01	
	2.0	2.02	-0.02	
	1.3	1.37	-0.07	
В	7.0	7.02	-0.02	0.998
	5.0	5.12	-0.12	
	3.0	3.14	-0.14	
	1.3	1.34	-0.04	
С	6.0	5.89	0.11	0.994
	4.0	3.99	0.01	
	2.0	2.03	-0.03	

HIV-1 Group M subtype	Nominal Concentration (log ₁₀ copies/mL)	HIV-1 VL XC Result (log ₁₀ copies/mL)	Delta (log ₁₀ copies/mL)	R ²
	1.3	1.33	-0.03	
D	6.0	5.83	0.17	0.995
	4.0	3.93	0.07	-
	2.0	2.00	0.00	-
	1.3	1.39	-0.09	-
F	6.0	5.74	0.26	0.988
	4.0	3.83	0.17	-
	2.0	1.79	0.21	-
	1.3	1.12	0.18	-
G	6.0	5.89	0.11	0.994
	4.0	3.92	0.08	-
	2.0	1.95	0.05	-
	1.3	1.16	0.14	-
Н	5.0	4.92	0.08	0.988
	4.0	3.94	0.06	
	2.0	1.99	0.01	-
	1.3	1.52	0.08	-
J	2.3	2.36	-0.05	NA ^a
	2.0	2.05	-0.05	
	1.3	1.42	-0.12	
К	4.0	3.86	0.14	0.980
	3.0	2.84	0.16]
	2.0	1.90	0.10	
	1.3	1.11	0.19]

^a Linear regression analysis was not performed for HIV-1 Group M subtype J and CRF-A/B due to unavailability of specimens spanning a large concentration range.

HIV-1 CRF	Nominal Concentration (log ₁₀ copies/mL)	HIV-1 VL XC Result (log ₁₀ copies/mL) Delta (log ₁₀ copies/mL)		R ²
CRF-A/B	2.3	2.39	-0.09	NA ^a
	2.0	1.97	0.03	
	1.3	1.32	-0.02	
CRF-A/E	6.0	5.95	0.05	0.992
	4.0	3.97	0.03	
	2.0	1.96	0.04	
	1.3	1.11	0.19	
CRF-A/G	6.0	5.87	0.13	0.991
	4.0	3.90	0.10	
	2.0	1.86	0.14	
	1.3	1.13	0.17	
CRF-B/C	6.0	5.70	0.30	0.995
	4.0	3.74	0.26	
	2.0	1.81	0.19	
	1.3	1.11	0.19	
CRF-06	7.0	6.94	0.06	0.997
	5.0	5.04	-0.04	
	3.0	3.05	-0.05	
	1.3	1.24	0.06	<u> </u>

Table 7. Analytical Reactivity (Inclusivity) for the HIV-1 VL XC Test, HIV-1 CRF's

^a Linear regression analysis was not performed for HIV-1 Group M subtype J and CRF-A/B due to unavailability of specimens spanning a large concentration range.

HIV-1 Group	Nominal Concentration (log ₁₀ copies/mL)	HIV-1 VL XC Result (log ₁₀ copies/mL)	Delta (log ₁₀ copies/mL)	R ²
N	7.0	6.78	0.22	0.994
	5.0	4.84	0.16	
	3.0	2.88	0.12	
	1.3	1.26	0.04	
0	6.0	5.96	0.04	0.995
	4.0	4.07	-0.07	
	2.0	2.12	-0.12	
	1.3	1.54	-0.24	
Р	5.0	5.17	-0.17	0.996

Table 8. Analytical Reactivity (Inclusivity) for the HIV-1 VL XC Test, HIV-1 Group N, Group O and Group P

HIV-1 Group	Nominal Concentration (log ₁₀ copies/mL)	HIV-1 VL XC Result (log ₁₀ copies/mL)	Delta (log ₁₀ copies/mL)	R ²
	4.0	4.21	-0.21	
	2.0	2.21	-0.21	
	1.3	1.51	-0.21	

In addition, analytical reactivity (inclusivity) for the HIV-1 VL XC test was demonstrated by testing HIV-1 specimens as shown in Table 9, representing HIV-1 Group M, subtypes A, B, C, D, F, G, H, J, K, CRF-A/E, CRF-A/G, CRF-B/C, group N and Group O. Each specimen was diluted to 3xLLoQ in K2 EDTA plasma and tested with one kit lot of the HIV-1 VL XC test. All samples tested at 3xLLoQ were reported as HIV-1 detected (Table 9).

HIV-1 Group	Subtype/CRF	Number of Samples Tested	Number of Samples Reported as HIV-1 Detected
М	A	10	10
	В	10	10
	С	10	10
	D	10	10
	F	10	10
	G	10	10
	Н	10	10
	J	4	4
	К	8	8
	CRF-A/E	10	10
	CRF-A/G	11	11
	CRF-B/C	5	5
Ν	NA	1	1
0	NA	10	10

Table 9. HIV-1 Specimens Tested at 3xLLoQ

18.6 Analytical Specificity (Exclusivity)

The analytical specificity of the HIV-1 VL XC test was evaluated by adding potentially cross-reactive or interfering organisms at a concentration of 1 x 10⁶ CFU/mL for microorganisms, or \geq 1 x 10⁵ copies/mL or TCID₅₀ for viruses into HIV-1 negative K2 EDTA plasma and K2 EDTA plasma containing HIV-1 reference material at a concentration of approximately 3xLLoQ. The HIV-1 reference material used was calibrated to the WHO 4th International standard for HIV-1 (NIBSC code: 16/194). Tested organisms are shown in Table 10. None of the tested organisms showed cross-reactivity or interfered with the quantification of the HIV-1 VL XC test.

Virus	Bacteria	Fungi/Yeast	Parasites
Chikungunya virus	Mycobacterium tuberculosis	Candida Albicans	Leishmania Major
Cytomegalovirus	Propionibacterium acnes	Candida Glabrata	Plasmodium Falciparum
Epstein-Barr virus	Staphylococcus aureus	Candida Tropicalis	Trypanosoma brucei
Hepatitis A virus	Staphylococcus epidermidis	Pneumocystis <i>jirovecii</i>	Trypanosoma cruzi
Hepatitis B virus	Staphylococcus haemolyticus		
Hepatitis C virus			
Herpes simplex virus 1			
Herpes simplex virus 2			
Human Herpesvirus 6			
Human Immunodeficiency virus 2			
Human T-cell lymphotropic virus type 1			
Human T-cell lymphotropic virus type 2			
Influenza virus A			

Table 10. Analytical Specificity Organisms

18.7 Potentially Interfering Substances

The susceptibility of the HIV-1 VL XC test to interference by elevated levels of endogenous substances, by drugs prescribed to HIV-1 infected patients or for those who may have co-infections or other co-morbidity, and autoimmune disease markers was evaluated. The inhibitory effects were evaluated in presence and absence of HIV-1 reference material at a concentration of approximately 3xLLoQ. The HIV-1 reference material used was calibrated to the WHO 4th International standard for HIV-1 (NIBSC code: 16/194).

Elevated levels of the endogenous substances shown in Table 11 were shown to not interfere with the quantification of the HIV-1 VL XC test or impact the specificity of the test when tested in presence and absence of HIV-1 RNA. All specimens tested in presence of HIV-1 RNA and the endogenous substance was quantified within \pm 0.5 log₁₀ copies/mL of the HIV-1 positive reference specimen. All specimens tested in absence of HIV-1 RNA were reported as HIV-1 Not Detected demonstrating that there was no impact on the specificity of the HIV-1 VL XC test.

Substance	Tested Concentration
Albumin	9 g/dL
Bilirubin	40 mg/dL
Hemoglobin	1000 mg/dL
Human DNA	0.4 mg/dL
Triglycerides	3000 mg/dL

Table 11. Endogenous Substances and Concentration Tested

The drug components as shown in Table 12 were shown to not interfere with the quantification or impact the specificity of the HIV-1 VL XC test when tested at three times peak level concentration (C_{max}) in the presence and absence of HIV-1 RNA.

Pool	Drugs
1	Zidovudine, Clarithromycin, Interferon alfa-2b, Maraviroc, Rilpivirine, Ganciclovir
2	Abacavir sulfate, Peginterferon 2a, Ribavirin, Emtricitabine, Adefovir dipivoxil, Entecavir, Valganciclovir HCl
3	Tenofovir disoproxil fumarate, Lamivudine, 3TC, Raltegravir, Etravirine
4	Stavudine, d4T, Efavirenz, Lopinavir, Ciprofloxacin, Indinavir sulfate, Acyclovir
5	Nevirapine, Azithromycin, Telbivudine, Foscarnet ^a , Cidofovir
6	Fosamprenavir calcium, Elvitegravir, Darunavir, Cobicistat, Atazanavir
7	Paritaprevir, Simeprevir
8	Daclatasvir, Elbasvir, Ledipasvir, Ombitasvir, Glecaprevir, Velpatasvir, Dasabuvir
9	Dolutegravir, Bictegravir, Doravirine, Maraviroc
10	Acetaminophen, Acetylsalicylic acid, Atorvastatin, Loratadine
11	Nadolol, Ascorbic acid, Phenylephrine, Ibuprofen
12	Artemether, Desethylamodiaquine, Mefloquine, Quinine
13	Primaquine, Chloroquine, Doxycycline
14	Rifampin, INH, Ethambutol, Pyrazinamide
15	Moxifloxacin, Levofloxacin, Amikacin, Bedaquiline ^a
16	Trimethoprim/Sulfamethoxazole, Gentamicin, Metronidazole, Ceftriaxone

Table 12. Drug Pools Tested

^a Tested individually instead of in combination with other drug components

Testing of K2 EDTA plasma specimens from five individuals positive for each of the autoimmune disease markers; systemic lupus erythematosus (SLE), anti-nuclear antibodies (ANA) or rheumatoid factor (RF) were shown to not interfere with the quantification of the HIV-1 VL XC test or impact the specificity of the test when tested in presence and absence of HIV-1 RNA.

18.8 Matrix Equivalency (K2 EDTA and PPT-EDTA)

Matrix equivalency for the HIV-1 VL XC test was conducted with matched clinical specimens from 50 HIV-1 positive individuals and 25 HIV-1 negative blood donors collected in K2 EDTA and PPT-EDTA collection tubes. The HIV-1 titers of the matched specimens (K2 EDTA and PPT-EDTA) from HIV-1 positive individuals covered the quantitative range of the test, 40-1x10⁷ copies/mL.

Matrix equivalency for the HIV-1 VL XC test was demonstrated as shown in Figure 13. All HIV-1 positive specimens collected in PPT-EDTA media produced concentrations of HIV-1 RNA within \pm 0.5 log₁₀ copies/mL of the HIV-1 positive specimen collected in K2 EDTA media when tested with the HIV-1 VL XC test. All 25 matched HIV-1 negative specimens were reported as HIV-1 Not Detected.



Figure 13. Linear Regression of HIV-1 titer (log₁₀ copies/mL), PPT-EDTA plasma versus K2 EDTA plasma

18.9 Whole System Failure Rate

The whole system failure rate for the HIV-1 VL XC test was determined by testing 100 replicates of K2 EDTA plasma spiked with a HIV-1 subtype B specimen calibrated to the WHO 4th International Standard for HIV-1 (NIBSC code 16/194). The K2 EDTA plasma was spiked to a target concentration of 60 copies/mL and tested with one kit lot of the HIV-1 VL XC test.

The results of this study showed that all 100 replicates were valid and reported HIV-1 positive, resulting in a whole system failure rate of 0%.

18.10 Carry Over Contamination

A high titer HIV-1 positive specimen (>1 x 10⁷ copies/mL) was tested, immediately followed by testing a HIV-1 negative specimen in the same GeneXpert instrument module. The procedure was repeated twenty (20) times in two different modules. The carryover rate for the HIV-1 VL XC test was 0%.

19 Performance Characteristics – Clinical Performance

19.1 Specificity

The specificity of the HIV-1 VL XC test was evaluated using 500 EDTA plasma specimens from HIV-1 negative blood donors. None of the 500 specimens tested were detected by the HIV-1 VL XC test equating to 100% specificity (95% CI = 99.2-100.0).

19.2 Method Correlation

A multi-site study was conducted to evaluate the performance of the HIV-1 VL XC test relative to a nucleic acid amplification test (NAAT) comparator method using fresh and frozen human plasma specimens collected from known HIV-1 infected individuals. Of the 362 specimens, each from unique individuals, 206 (56.9%) were collected from male subjects. Most individuals (94.5%; 342/362) were in the age range of 22 to 59 years. Classification of specimens by HIV-1 Group M subtypes in this study population were shown to be 25.1% subtype B, 16.1% non-B subtype and 58.8% subtype unknown.

There were 21 indeterminate results of which 14 were resolved after retesting. The final indeterminate rate was 1.93% (7/362).

Of the 362 specimens, 328 were within the quantitation range of Xpert HIV-1 VL XC and the comparator test. The Deming regression shows high correlation between the Xpert HIV-1 VL XC test and the comparator method with a slope of 0.9625 and intercept of 0.0198. The R2 was 0.9561.



Figure 14. Correlation between the HIV-1 VL XC Test Relative to a Comparator Method

20 References

- 1. Mellors JW, Rinaldo CR, Jr., Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167–1170.
- 2. World Health Organization. What's new in Treatment Monitoring: Viral Load and CD4 Testing. Geneva. WHO. 2017
- **3.** WHO International Standard; 4th HIV-1 International Standard (NIBSC code: 16/1094). National Institute for Biological Standards and Control; 2017.
- Centers for Disease Control and Prevention. Biosafety in Microbiological and Biomedical Laboratories. Richmond JY and McKinney RW (eds) (1993). HHS Publication number (CDC) 93-8395.
- Clinical and Laboratory Standards Institute. Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline. Document M29 (refer to latest edition).
- 6. World Health Organization. Safe management of wastes from health-care activities. 2nd Edition. WHO, 2014. Accessed July 24, 2020 at http://www.who.int/water_sanitation_health/publications/wastemanag/en/
- REGULATION (EC) No 1272/2008 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 2008 on the classification labeling and packaging of substances and mixtures amending and repealing, List of Precautionary Statements, Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006.
- Occupational Safety and Health Standards, Hazard Communication, Toxic and Hazard Substances (March 26, 2012) (29 C.F.R., pt. 1910, subpt. Z).
- 9. Clinical and Laboratory Standards Institute. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline Second Edition. CLSI document EP17-A2. Wayne, PA, 2012.

- **10.** Clinical and Laboratory Standards Institute. Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline—Third Edition. CLSI document EP05-A3. Wayne, PA, 2014.
- 11. Clinical and Laboratory Standards Institute. Evaluation of Linearity of Quantitative Measurement Procedures: A Statistical Approach. Approved Guideline. CLSI document EP06-A. Wayne, PA, 2003.

21 Cepheid Headquarters Locations

Corporate Headquarters

Cepheid 904 Caribbean Drive Sunnyvale, CA 94089 USA

Telephone: + 1 408 541 4191 Fax: + 1 408 541 4192 www.cepheid.com

European Headquarters

Cepheid Europe SAS Vira Solelh 81470 Maurens-Scopont France

Telephone: + 33 563 825 300 Fax: + 33 563 825 301 www.cepheidinternational.com

22 Technical Assistance

Before Contacting Us

Collect the following information before contacting Cepheid Technical Support:

- Product name
- Lot number
- Serial number of the instrument
- Error messages (if any)
- Software version and, if applicable, Computer Service Tag Number

Report serious incidents associated with the test to Cepheid and the competent authority of the member state in which the serious incident occurred.

United States

Telephone: + 1 888 838 3222 Email: techsupport@cepheid.com

France

Telephone:+ 33 563 825 319 Email: support@cepheideurope.com

Contact information for all Cepheid Technical Support offices is available on our website:www.cepheid.com/en/support/ contact-us

23 Table of Symbols

Symbol	Meaning
REF	Catalog number
IVD	<i>In vitro</i> diagnostic medical device
CE	CE marking – European Conformity
8	Do not reuse
LOT	Batch code
i	Consult instructions for use
	Manufacturer
53	Country of manufacture
Σ	Contains sufficient for <i>n</i> tests
CONTROL	Control
	Expiration date
X	Temperature limitation
8	Biological risks
	Caution
\Diamond	Warning
CH REP	Authorized Representative in Switzerland
	Importer



Cepheid AB Röntgenvägen 5 SE-171 54 Solna, Sweden



Cepheid Switzerland GmbH Zürcherstrasse 66 Postfach 124, Thalwil CH-8800 Switzerland



Cepheid Switzerland GmbH Zürcherstrasse 66 Postfach 124, Thalwil CH-8800 Switzerland



24 Revision History

Description of Changes: From 302-4124 Rev. C to Rev. D

Purpose: Addition of Swiss Importer details.

Section	Description of Change
23	Addition of Swiss Importer symbol, CH REP symbol, and related addresses.